Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients - A cost-effectiveness analysis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 4, 2006, Pages 149-153

  You, J H S ^a   Lau, W ^a   Lee, I Y C ^a   Yung, M ^a   Ching, J Y L ^b   Chan, F K L ^b   Lee, K K C ^a  

^a Prince of Wales Hospital   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cost effectiveness analysis; Helicobacter pylori; Non steroidal anti inflammatory drug; Peptic ulcer disease

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CHINESE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ERADICATION THERAPY; ESOPHAGOGASTRODUODENOSCOPY; FOLLOW UP; HEALTH CARE COST; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK POPULATION; HONG KONG; HUMAN; INFECTION CONTROL; LONG TERM CARE; MAJOR CLINICAL STUDY; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 33645735400     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp44149     Document Type: Article

References (24)

1. Bjorkman DJ. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med. 1999; 107 (Suppl 3A): 3S-10S.
2. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000; 22: 283-297.
3. Chan FKL, Sung JJY, Chung SCS et al. Randomized trial of eradication of Helicobacter pylori before nonsteroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997; 350: 975-979.
4. Chan FKL, To KF, Wu JCY et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002; 359: 9-13.
5. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programs (2nd ed). New York: Oxford University Press; 1997.
6. Gabriel SE, Jaakkimainen L, Bombardier C. Risks for serious gastrointestinal complications related to the use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med. 1991; 115: 787-796.
7. Graham DY, Lidsky MD, Cox AM et al. Long-term non-steroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology. 1991; 100: 1653-1657.
8. Griffin MR, Piper JM, Daugherty JR et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991; 114: 257-263.
9. Henry D, Lim LL, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996; 312: 1563-1566.
10. Heresbach D, Raoul JL, Bretagne JF et al. Helicobacter pylori: a risk and severity factor of non-steroidal antiinflammatory drug induced gastropathy. Gut. 1992; 33: 1608-1611.
11. Hong Kong SAR, China. Website http://www.info.gov.hk
12. Huang JQ, Sirdhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002; 359: 14-22.
13. Langman MJS, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drug. Lancet 1994; 343: 1075-1078.
14. Levin TR, Schmittdiel JA, Kunz K et al. Costs of acid-related disorders to a health maintenance organization. Am J Med. 1997; 103: 520-528.
15. Li EKM, Sung JY, Suen R et al. Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs. Scand J Rheumatol. 1996; 25: 42-46.
16. Loeb DS, Talley NJ, Ahlquist DA, Carpenter HA, Zinsmeister AR. Long-term non-steroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology. 1992; 102: 1899-1905.
17. Martin DF, Montgomery E, Dobek AS, Patrissi GA, Peura DA. Campylobacter pylori NSAIDs, and smoking: risk factors for peptic ulcer disease. Am J Gastroenterol. 1989; 84: 1268-1272.
18. Publig W, Wustinger C, Zandl C. Non-steroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal ulcers mainly in Helicobacter pylori carriers. Wien Klin Wochenschr. 1994; 106: 276-279.
19. Scheiman JM, Bandekar RR, Chernew ME, Fendrick AM. Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis. Aliment Pharmacol Ther. 2001; 15: 63-71.
20. Shallcross TM, Rathbone BJ, Wyatt JI, Heatley RV. Helicobacter pylori-associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 1990; 4: 515-522.
21. Taha AS, Nakshabendi I, Lee FD, Sturrock RD, Russell RI. Chemical gastritis and Helicobacter pylori-related gastritis in patients receiving non-steroidal anti-inflammatory drugs: comparison and correlation with peptic ulceration. J Clin Pathol. 1992; 45: 135-139.
22. Tenenbaum J. The epidemiology of nonsteroidal anti-inflammatory drugs. Can J Gastroenterol. 1999; 13: 119-122.
23. The report of the digestive health initiative international update conference on Helicobacter pylori. Gastroenterology. 1997; 113 (Suppl): S4-8.
24. Upadhyay R, Howatson A, McKinlay A, Danesh BJZ, Sturrock RD, Russell RI. Campylobacter pylori-associated gastritis in patients taking non-steroidal anti-inflammatory drugs. Br J Rheumatol. 1988; 27: 113-116.